Valemetostat + Atezolizumab
Phase 1Recruiting 3 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Jan 29, 2025 → Jan 1, 2027
NCT ID
NCT06807632About Valemetostat + Atezolizumab
Valemetostat + Atezolizumab is a phase 1 stage product being developed by Daiichi Sankyo for Extensive-stage Small-cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06807632. Target conditions include Extensive-stage Small-cell Lung Cancer.
What happened to similar drugs?
0 of 7 similar drugs in Extensive-stage Small-cell Lung Cancer were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06807632 | Phase 1 | Recruiting |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer